Azacitidine induces demethylation of p16INK4a and inhibits growth in adult T-cell leukemia/lymphoma

International Journal of Molecular Medicine

Volumn 28, Issue 5, 2011, Pages 835-839

  Uenogawa, Kumi ^a   Hatta, Yoshihiro ^a   Arima, Naomichi ^b   Hayakawa, Satoshi ^a   Sawada, Umihiko ^a   Aizawa, Shin ^a   Yamamoto, Tatsuo ^a   Takeuchi, Jin ^a  

^a NIHON UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Azacitidine; Methylation; p14ARF; p16INK4a

Indexed keywords

AZACITIDINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; EPIGENETICS; EXON; GENE EXPRESSION; GENE INACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; METHYLATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL LEUKEMIA;

AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; METHYLATION; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 80053122382     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.756     Document Type: Article

References (43)

1. Yoshida M, Miyoshi I and Hinuma Y: Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 79: 2031-2035, 1982. (Pubitemid 12088563)
2. Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79: 428-437, 1991.
3. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara A, Sano M, Ikeda S, Takatsuki K, Kozuru M, Araki K, Kawano F, Niimi M, Tobinai K, Hotta T and Shimoyama M: A new G-CSF-supported combination chemotherapy: LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 113: 375-382, 2001. (Pubitemid 32523141)
4. Kiyokawa T, Seiki M, Imagawa K, Shimizu F and Yoshida M: Identification of a protein (p40x) encoded by a unique sequence pX of a human T-cell leukemia virus type I. Gann 75: 747-751, 1984. (Pubitemid 14015671)
5. Tajima K: The fourth nationwide study of adult T-cell leukemia/ lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer 45: 237-243, 1990.
6. Tokudome S, Tokunaga O, Shimamoto Y, Miyamoto Y, Sumida I, Kikuchi M, Takeshita M, Ikeda T, Fujiwara K, Yoshihara M, Yanagawa T and Nishizumi M: Incidence of adult T-cell leukemia/ lymphoma among human T-lymphotropic virus type 1 carriers in Saga, Japan. Cancer Res 49: 226-228, 1989. (Pubitemid 19024436)
7. Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M and Koeffler HP: Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood 85: 2699-2704, 1995.
8. Hatta Y, Yamada M, Tomonaga M and Koeffler HP: Extensive analysis of the retinoblastoma gene in adult T cell leukemia/ lymphoma (ATL). Leukemia 11: 984-989, 1997. (Pubitemid 27345945)
9. Hatta Y, Spirin K, Tasaka T, Morosetti R, Said JW, Yamada Y, Tomonaga M and Koeffler HP: Analysis of p18INK4C in adult T-cell leukaemia and non-Hodgkin's lymphoma. Br J Haematol 99: 665-667 1997. (Pubitemid 27519871)
10. Fujiwara H, Arima N, Hashimoto-Tamaoki T, Matsushita K, Ohtsubo H, Arimura K, Hidaka S and Tei C: Alteration of p16 (CDKN2) gene is associated with interleukin-2-induced tumor cell growth in adult T-cell leukemia. Exp Hematol 27: 1004-1009, 1999. (Pubitemid 29275388)
11. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH and Cannon-Albright LA: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8: 23-26, 1994.
12. Tam SW, Shay JW and Pagano M: Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res 54: 5816-5820, 1994.
13. Quelle DE, Zindy F, Ashmun RA and Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000, 1995. (Pubitemid 26006540)
14. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G and Kamb A: Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55: 2988-2994, 1995.
15. Zhang Y, Xiong Y and Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734, 1998. (Pubitemid 28155312)
16. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF and Sherr CJ: Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95: 8292-8297, 1998. (Pubitemid 28326106)
17. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D: 5'CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN2/MTS1 in human cancers. Nat Med 1: 686-692, 1995.
18. Endo M, Kobayashi C, Setsu N, Takahashi Y, Kohashi K, Yamamoto H, Tamiya S, Matsuda S, Iwamoto Y, Tsuneyoshi M and Oda Y: Prognostic significance of p14ARF, p15INK4b and p16INK4a inactivation in malignant peripheral nerve sheath tumors. Clin Cancer Res 17: 3771-3782, 2011.
19. Jardin F, Jais JP, Molina TJ, Parmentier F, Picquenot JM, Ruminy P, Tilly H, Bastard C, Salles GA, Feugier P, Thieblemont C, Gisselbrecht C, De Reynies A, Coiffier B, Haioun C and Leroy K: Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood 116: 1092-1104, 2010.
20. Matsushita C, Yang Y, Takeuchi S, Matsushita M, Van Dongen JJ, Szczepanski T, Bartram CR, Seo H, Koeffler HP and Taguchi H: Aberrant methylation in promoter-associated CpG islands of multiple genes in relapsed childhood acute lymphoblastic leukemia. Oncol Rep 12: 97-99, 2004.
21. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA and Holland JF: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20: 2429-2440, 2002. (Pubitemid 34525728)
22. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL and Larson RA; Cancer and Leukemia Group B: Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24: 3895-3903, 2006. (Pubitemid 46630737)
23. Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S and Galili N: Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer 113: 1596-1604, 2008.
24. Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD and Seymour JF: Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer: Jan 10, 2011 (Epub ahead of print).
25. Christman JK: 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21: 5483-5495, 2002.
26. Miyamoto K, Tomita N, Ishii A, Nishizaki T and Togawa A: Establishment and characterization of adult T-cell leukemia viruscontaining B-cell lines derived from peripheral blood of adult T-cell leukemia patients. Gann 75: 655-659, 1984. (Pubitemid 14062923)
27. Arima N, Molitor JM, Smith MR, Kim JH, Daitoku Y and Greene W: Human T-cell leukemia virus type I Tax induces expression of the Rel-related family of kB enhancer-binding proteins: evidence for a pre-translational component of regulation. J Virol 65: 6892-6899, 1991.
28. Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996. (Pubitemid 26296693)
29. Tsujie M, Yamamoto H, Tomita N, Sugita Y, Ohue M, Sakita I, Tamaki Y, Sekimoto M, Doki Y, Inoue M, Matsuura N, Monden T, Shiozaki H and Monden M: Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer. Oncology 58: 126-136, 2000. (Pubitemid 30113863)
30. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB and Herman JG: Hypermethylation-associated inactivation of p14 (ARF) is independent of p16 (INK4a) methylation and p53 mutational status. Cancer Res 60: 129-133, 2000. (Pubitemid 30058742)
31. Okamoto T, Ohno Y, Tsugane S, Watanabe S, Shimoyama M, Tajima K, Miwa M and Shimotohno K: Multi-step carcinogenesis model for adult T-cell leukemia. Jpn J Cancer Res 80: 191-195, 1989. (Pubitemid 20027205)
32. Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997. (Pubitemid 27220766)
33. Kubbutat MH, Jones SN and Vousden KH: Regulation of p53 stability by Mdm2. Nature 387: 299-303, 1997. (Pubitemid 27220767)
34. Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC and Koeffler HP: Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet 86: 136-142, 1996. (Pubitemid 26074804)
35. Miller CW and Koeffler CW: Cyclin-dependent kinase inhibitors in human neoplasms. Leukemia 11 (Suppl 3): S370-S371, 1997.
36. Hebert J, Cayuela JM, Berkeley J and Sigaux F: Candidate tumorsuppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 84: 4038-4044, 1994.
37. Ohnishi H, Kawamura M, Ida K, Sheng XM, Hanada R, Nobori T, Yamamori S and Hayashi Y. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 86: 1269-1275, 1995.
38. Herman JH, Civin CI, Issa JJ, Collector MI, Sharkis SJ and Baylin SB: Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57: 837-841, 1997. (Pubitemid 27098005)
39. Robertson KD and Jones PA: The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 18: 6457-6473, 1998. (Pubitemid 28500536)
40. Egger G, Liang G, Aparicio A and Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463, 2004. (Pubitemid 38715140)
41. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Köhler G, Wijermans P, Jones PA and Lübbert M: Demethylation of a hypermethylated p16/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 100: 2957-2964, 2002.
42. Zhu WG, Dai Z, Ding H, Srinivasan K, Hall J, Duan W, Villalona-Caero MA, Plass C and Otterson GA: Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells. Oncogene 20: 7787-7796, 2001. (Pubitemid 33121952)
43. Nosaka K, Maeda M, Tamiya S, Sakai T, Mitsuya H and Matsuoka M: Increasing methylation of the CDKN2 gene is associated with the progression of adult T-cell leukemia. Cancer Res 60: 1043-1048, 2000. (Pubitemid 30129543)